Aurinia Pharmaceuticals Inc. (AUPH) is a biopharmaceutical company dedicated to developing innovative therapies for serious diseases, with a primary focus on lupus nephritis. Based in Victoria, Canada, the company utilizes its extensive drug development expertise to create and deliver impactful treatment solutions, targeting critical healthcare needs in major markets including Japan and China. Aurinia's commitment to enhancing patient outcomes positions it strategically in the evolving biopharmaceutical sector, with ongoing potential for growth as it addresses significant unmet medical needs.